- Home
- ยป
- Our Products
- »
- Pharmaceutical Tablets
Pharmaceutical Tablets
12mg Iverheal Ivermectin Tablet
Minimum Order Quantity: 10 Strip
Product Brochure
| Strength | 12mg |
| Usage | Human |
| Packaging Size | 1*10 Tablets |
| Dosage Form | Tablet |
| Prescription | Non Prescription |
| Usages | Parasitic Infection Treatment |
| Packaging Type | Strip |
| Brand | Healing Pharma |
| Shelf Life | 3 Years |
| Form | Tablet |
| Pack Size | 10x10 Tablet |
| Pack Type | Box |
Ivermectin 12 mg Tablet: Key Information
Overview
Ivermectin 12 mg is a well-known antiparasitic medicine used for treating several parasitic infections. It works by disrupting nerve and muscle function in parasites, causing paralysis and elimination. When used correctly, it is effective and generally well tolerated.
Indications
Ivermectin is indicated for:
• Strongyloidiasis
• Onchocerciasis (river blindness)
• Scabies, including resistant or crusted forms
• Head Lice as an alternative therapy
• Other parasitic conditions based on medical guidance
Its use should always follow confirmed diagnosis and approved treatment protocols.
Mechanism of Action
Ivermectin binds to chloride channels found in the nerve and muscle cells of parasites. This increases chloride flow, leading to paralysis and death. These channels are not present in humans, supporting ivermectin’s targeted activity and safety when dosed properly.
Dosage and Administration
The dose depends on body weight and the specific infection.
• Taken orally with water, often on an empty stomach.
• Some conditions require a single dose, while others may need repeat dosing.
• Only a healthcare professional should determine the correct schedule.
Avoid self-adjusting doses, as incorrect use increases risk of adverse effects.
Side Effects
Common Side Effects
• Mild dizziness
• Nausea or stomach discomfort
• Diarrhea
• Fatigue
• Itching or rash, sometimes linked to parasite die-off
Serious Side Effects
Seek medical attention for:
• Severe allergic reactions
• Confusion or neurological changes
• Vision problems
• Irregular heartbeat
• Intense skin reactions
Serious effects are uncommon but may occur if the drug is misused or interacts with other medicines.
Monitoring
• Patients with liver issues may need periodic checks.
• Those with heavy parasite load may experience inflammatory reactions and require supervision.
• Regular follow-up helps ensure safe and effective treatment.
Contraindications
Do not use ivermectin in:
• Known hypersensitivity to the drug
• Children under 15 kg without specialist advice
• Certain neurological conditions where caution is needed
Pregnant or breastfeeding individuals should use ivermectin only after professional evaluation.
Drug Interactions
Report all medicines and supplements to your healthcare provider. Drugs affecting the nervous system, anticoagulants, or those sharing similar metabolic pathways may interact with ivermectin.
Storage Instructions
Store at room temperature, away from heat and moisture. Keep tablets in their original packaging and out of children’s reach.
Patient Counseling Information
• Explain the purpose of treatment and how to take the tablet correctly.
• Do not exceed the prescribed dose.
• Report unusual symptoms promptly.
• Avoid self-medicating or sharing the medicine.
Conclusion
Ivermectin 12 mg remains an important option for treating several parasitic infections. When prescribed and monitored by a qualified professional, it provides reliable and safe therapeutic outcomes.
2mg Progynova Estradiol Tablet
Product Brochure
| Strength | 2 mg |
| Packaging Size | 28 Tablets in 1 Strip |
| Composition | Estradiol 2 mg |
| Brand Name | Progynova |
| Manufacturer | Bayer Zydus Pharma Pvt Ltd |
| Treatment | Hormone Replacement Therapy |
2 mg Progynova Estradiol Tablet
Overview:
Progynova 2 mg (Estradiol) is a synthetic form of estradiol, a type of estrogen, used primarily in hormone replacement therapy (HRT) for menopausal symptoms and estrogen deficiency. It helps to alleviate common symptoms of menopause such as hot flashes, vaginal dryness, and osteoporosis. Progynova is also used in cases of hypoestrogenism, where the body does not produce enough estrogen, and can be part of HRT regimens for women who have undergone a hysterectomy.
Indications:
Progynova 2 mg is prescribed for:
- Menopausal Symptoms: To treat hot flashes, mood changes, and vaginal dryness due to the reduction of estrogen levels after menopause.
- Osteoporosis Prevention: To reduce bone loss and the risk of fractures in postmenopausal women.
- Hypoestrogenism: For women with estrogen deficiency due to ovarian failure, premature menopause, or hormonal imbalances.
- Hormone Replacement Therapy (HRT): For women who have had a hysterectomy, to balance hormone levels and manage symptoms related to low estrogen.
Mechanism of Action:
Estradiol, the active ingredient in Progynova, binds to estrogen receptors in various tissues such as the reproductive organs, bones, and cardiovascular system. It helps regulate vital functions like the menstrual cycle, bone density, and cardiovascular health. By replenishing estrogen, Progynova eases menopause-related symptoms and protects bone health by preventing osteoporosis.
Dosage and Administration:
- Recommended Dose: Typically, 2 mg daily is prescribed. The dose may be adjusted based on response.
- Administration: Taken orally, with or without food, as part of a hormone replacement therapy regimen.
- Duration: The length of treatment depends on individual needs and response.
Side Effects:
- Common Side Effects: Nausea, headache, weight gain, breast tenderness, and bloating.
- Serious Side Effects: Increased risk of blood clots, stroke, heart disease, and endometrial cancer (especially when used without a progestogen).
Precautions:
Progynova should be used cautiously in women with a history of breast cancer, liver disease, or blood clots. Regular monitoring for blood pressure, liver function, and bone health is advised. Pregnancy and breastfeeding are contraindications.
Storage:
Store at room temperature (15°C to 30°C) away from light and moisture.
Conclusion:
Progynova 2 mg is an effective treatment for managing menopausal symptoms and preventing osteoporosis. Regular monitoring is essential for managing risks associated with long-term use.
Tenof em 300mg/200mg Tablet (Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg)
Product Brochure
| Dose/Strength | 300mg/200mg |
| Pack Size | 30 tablets |
| Strength | Tenofovir Disoproxil 300 mg, Emtricitabine 200 mg |
| Brand | Tenof EM |
| Packaging Size | 1x30Tablets |
| Brand Name | Tenof EM |
| Manufacturer By | Hetero Drugs Ltd |
| Treatment | HIV Infection |
Tenof EM Tablet (Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg)
Overview: Tenof EM is a fixed-dose combination tablet that contains tenofovir disoproxil fumarate and emtricitabine. It is used for the treatment of HIV-1 infection and for pre-exposure prophylaxis (PrEP) in individuals at high risk of HIV infection.
Indications:
- HIV Infection: For the treatment of HIV-1 infection in adults and pediatric patients as part of a comprehensive antiretroviral therapy regimen.
- Pre-exposure Prophylaxis (PrEP): For individuals at high risk of HIV to reduce the risk of acquiring the virus.
Mechanism of Action:
- Tenofovir Disoproxil Fumarate: A nucleotide reverse transcriptase inhibitor (NRTI) that inhibits the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA.
- Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI) that also works by inhibiting reverse transcriptase, thus reducing viral replication.
Dosage and Administration:
- Recommended Dose: Typically, one tablet taken orally once daily.
- Administration: Can be taken with or without food. It is important to take it at the same time each day for maximum effectiveness.
Side Effects: Common side effects may include:
- Nausea
- Diarrhea
- Fatigue
- Headache
- Possible kidney function changes (particularly with tenofovir)
Warnings and Precautions:
- Renal Function: Regular monitoring of kidney function is important, especially in patients with pre-existing kidney issues.
- Liver Function: Monitor liver function, particularly in patients with a history of liver disease.
- Bone Health: Long-term use may affect bone mineral density; monitoring may be necessary.
Contraindications:
- Hypersensitivity to any of the components.
- Severe renal impairment.
Drug Interactions: Tenof EM may interact with other medications, particularly those affecting kidney function or renal excretion. Patients should inform their healthcare provider about all medications and supplements they are taking.
Storage Instructions: Store at room temperature, away from moisture and light. Keep out of reach of children.
Patient Counseling Information:
- Advise patients to take the medication as prescribed and not to miss doses.
- Discuss the importance of regular follow-up appointments for monitoring viral load and kidney function.
- Instruct patients to report any unusual side effects, especially related to kidney health or gastrointestinal symptoms.
Tenof EM Tablet (Tenofovir Disoproxil Fumarate and Emtricitabine) is an effective treatment option for managing HIV-1 infection and for PrEP. Proper adherence to dosing, monitoring for side effects, and patient education are essential for optimizing treatment outcomes. Always consult a healthcare provider for personalized treatment recommendations.
50mg Instgra Dolutegravir Tablets
Product Brochure
| Strength | 50 mg |
| Variant | Dolutegravir |
| Pack Size | 30 tablets |
| Dose Strength | 50 mg |
| Packaging Size | 30 Tablets in 1 Bottle |
| Composition | Dolutegravir |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Brand Name | Instgra 50 mg |
| Treatment | HIV Infection |
Instgra (Dolutegravir) 50 mg Tablets
Overview: Instgra contains dolutegravir, an integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection. It is effective in reducing viral load and improving immune function as part of a comprehensive antiretroviral therapy regimen.
Indications:
- HIV Infection: Indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 12 years and older, as part of a combination therapy.
Mechanism of Action: Dolutegravir inhibits the integrase enzyme, which is essential for the integration of viral DNA into the host genome. This action prevents the replication of the virus, effectively reducing its presence in the body.
Dosage and Administration:
- Recommended Dose: The usual dose is 50 mg taken orally once daily. In some cases, it may be taken twice daily based on specific patient factors.
- Administration: Can be taken with or without food. Consistency in timing is important for optimal effectiveness.
Side Effects: Common side effects may include:
- Insomnia
- Headache
- Fatigue
- Nausea
- Diarrhea
- Weight gain (in some patients)
Warnings and Precautions:
- Hypersensitivity Reactions: Monitor for signs of serious allergic reactions, including skin rash or liver problems.
- Liver Function: Patients with a history of liver disease should be closely monitored.
- Drug Interactions: Dolutegravir may interact with other medications, particularly those affecting liver enzymes. Discuss all current medications with a healthcare provider.
Contraindications:
- Hypersensitivity to dolutegravir or any components of the formulation.
- Not recommended during pregnancy unless the benefits outweigh the risks.
Drug Interactions: Dolutegravir may interact with various medications, especially those that influence CYP450 enzymes. It’s crucial to discuss all medications and supplements with a healthcare provider.
Storage Instructions: Store at room temperature, away from moisture and light. Keep out of reach of children.
Patient Counseling Information:
- Advise patients to take the medication as prescribed and not to miss doses to maintain viral suppression.
- Discuss the importance of regular follow-up appointments for monitoring HIV viral load and overall health.
- Instruct patients to report any unusual side effects, particularly severe allergic reactions.
Instgra (Dolutegravir) 50 mg Tablets are an effective option for managing HIV-1 infection. Proper adherence to dosing, monitoring for side effects, and patient education are essential for optimizing treatment outcomes. Always consult a healthcare provider for personalized treatment recommendations.
Sprycel Dasatinib 70mg Tablet
Product Brochure
| Strength | 70 mg |
| Form | Tablet |
| Pack Size | 1*60 Tablet |
| Pack Type | Box |
| Brand Name | Sprycel |
| Prescription/Non prescription | Prescription |
Sprycel Dasatinib 70mg Tablet
Overview:
Sprycel (generic name Dasatinib) is an oral tyrosine kinase inhibitor (TKI) used in the treatment of certain types of leukemia and other cancers. It works by inhibiting the action of abnormal kinase enzymes that are involved in the uncontrolled growth of cancer cells. By blocking these enzymes, Dasatinib helps to prevent cancer cell proliferation, ultimately slowing or stopping tumor growth. It is primarily used in the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), particularly in cases that are resistant or intolerant to other treatments.
Indications:
Sprycel 70mg Tablet is indicated for:
- Chronic Myelogenous Leukemia (CML): In both newly diagnosed and previously treated patients who are resistant or intolerant to imatinib.
- Acute Lymphoblastic Leukemia (ALL): In patients with Philadelphia chromosome-positive ALL, either newly diagnosed or those who have relapsed or are resistant to other treatments.
Mechanism of Action:
Dasatinib is a multi-targeted tyrosine kinase inhibitor that blocks the activity of several kinases involved in cancer cell growth, including the BCR-ABL1 fusion protein in CML and ALL. This protein is responsible for the uncontrolled proliferation of leukemia cells. By inhibiting BCR-ABL1 and other kinases, Dasatinib disrupts signaling pathways that drive the growth of cancer cells, leading to cell cycle arrest and apoptosis (programmed cell death).
Dosage and Administration:
- Recommended Dose: The usual dose is 70mg once daily for CML and ALL patients, though the dose may vary depending on individual response and tolerance.
- Administration: Take the tablet once daily, with or without food. Swallow the tablet whole; do not crush or chew.
- Missed Dose: If a dose is missed, take it as soon as possible unless it’s close to the next dose. Do not take two doses at once.
Side Effects:
Common side effects include:
- Fatigue, headache, nausea, diarrhea, rash, and muscle pain.
Serious side effects may include: - Bleeding complications: Risk of severe bleeding or bruising.
- Cardiac issues: Heart failure, arrhythmias, and fluid retention.
- Liver toxicity: Elevated liver enzymes and liver damage.
Precautions:
- Bleeding Risk: Monitor for signs of bleeding, including unusual bruising or nosebleeds.
- Heart Health: Regular monitoring of heart function is important, especially for patients with existing heart conditions.
- Pregnancy: Sprycel is contraindicated during pregnancy as it can harm the fetus.
Storage:
Store Sprycel tablets at room temperature (20°C to 25°C), away from moisture and light. Keep out of reach of children.
Conclusion:
Sprycel (Dasatinib) is an effective treatment for chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). By inhibiting key enzymes involved in cancer cell proliferation, it helps control the disease and improve patient outcomes. Regular monitoring for side effects, including bleeding, cardiac issues, and liver function, is crucial for patient safety.
100mg Invista Dasatinib Tablet
Product Brochure
| Strength | 100 mg |
| Form | Tablet |
| Pack Type | Box |
| Brand Name | Dr. Reddy's |
| Usages | Used To Treat CML |
| Shelf Life | 2 Years |
| Packaging Size | 3x10 Tablet |
Invista 100 mg Tablet
Overview:Invista 100 mg Tablets contain Methylprednisolone, a corticosteroid used to reduce inflammation and suppress the immune system. It is commonly prescribed to treat various inflammatory and autoimmune conditions, including arthritis, allergies, skin diseases, and certain types of cancer. Methylprednisolone works by mimicking the effects of cortisol, a hormone naturally produced by the adrenal glands. It helps reduce inflammation and the body's immune response, providing relief from symptoms such as swelling, pain, and redness.
Indications:Invista 100 mg Tablets are indicated for the treatment of:
- Inflammatory Conditions: Including rheumatoid arthritis, lupus, and other autoimmune disorders.
- Allergic Reactions: Such as severe allergies or skin conditions.
- Respiratory Diseases: For example, chronic obstructive pulmonary disease (COPD) and asthma exacerbations.
- Cancer Therapy: As part of the treatment for certain cancers, such as lymphoma, to manage symptoms.
- Other Conditions: Including skin disorders, inflammatory bowel disease, and eye conditions like uveitis.
Methylprednisolone is a synthetic corticosteroid that works by suppressing the immune system and reducing inflammation. It binds to specific receptors in the body, altering the expression of genes that regulate inflammation. This reduces the production of inflammatory substances like prostaglandins and cytokines, helping control symptoms associated with inflammatory and autoimmune conditions.
Dosage and Administration:- Recommended Dose: The usual dose of Invista 100 mg varies based on the specific condition being treated. For inflammatory conditions, doses typically start at 4-48 mg per day, depending on the severity of the condition. For cancer-related conditions, higher doses may be required.
- Administration: Take Invista 100 mg tablets with or without food, swallowed whole with a glass of water. It is crucial to follow the prescribed dosage regimen carefully to avoid side effects or complications.
- Common Side Effects: Weight gain, increased appetite, fluid retention, insomnia, and mood changes.
- Serious Side Effects: Long-term use may cause osteoporosis, gastric ulcers, hypertension, diabetes, and increased risk of infections. Prolonged use should be accompanied by regular monitoring by a healthcare provider.
- Infections: Methylprednisolone can suppress the immune system, making you more susceptible to infections. Avoid exposure to individuals with contagious diseases.
- Kidney and Liver Disease: Use with caution in patients with kidney or liver problems. Dosage adjustments may be needed.
- Pregnancy and Lactation: Invista should only be used during pregnancy if the benefits outweigh the risks. It is excreted in breast milk, so it is advised to avoid breastfeeding during treatment.
- Tapering: Do not abruptly stop taking Methylprednisolone. The dose should be gradually reduced to avoid withdrawal symptoms.
Store Invista 100 mg Tablets at room temperature (15°C to 30°C), away from heat, moisture, and direct light. Keep out of reach of children.
Conclusion:Invista 100 mg Tablets are a potent corticosteroid used to treat various inflammatory, autoimmune, and allergic conditions. When used as directed, Methylprednisolone helps manage symptoms and improve quality of life. However, long-term use can lead to serious side effects, so it is essential to be monitored regularly by a healthcare provider during treatment.
Paxzen Nirmatrelvir Ritonavir Tablet
Product Brochure
| Strength | 150 mg + 100 mg |
| Packaging Size | 30 Tablets in 1 Box |
| Composition | Nirmatrelvir 150 mg + Ritonavir 100 mg |
| Brand | Paxzen |
| Manufacturer | Zenara Pharma |
| Usage/Application | Coronavirus disease (COVID-19) |
Paxzen (Nirmatrelvir/Ritonavir Tablet)
Overview:
Paxzen is a combination tablet containing Nirmatrelvir and Ritonavir, used for the treatment of COVID-19 in patients at risk of developing severe disease. Nirmatrelvir is an antiviral drug that inhibits the activity of the SARS-CoV-2 virus by blocking the viral protease enzyme essential for viral replication. Ritonavir, an HIV protease inhibitor, is included in the combination to increase the effectiveness of Nirmatrelvir by slowing its metabolism in the body, allowing it to stay active longer.
Indications:
Paxzen is indicated for the treatment of COVID-19 in adults and pediatric patients (12 years and older, weighing at least 40 kg) who are at risk of progressing to severe disease, including hospitalization or death. It is recommended for use in patients with mild-to-moderate COVID-19 who have symptoms and who are at high risk for severe disease due to factors such as age, comorbidities, or immunocompromised states.
Mechanism of Action:
- Nirmatrelvir: This component inhibits the SARS-CoV-2 main protease (Mpro), preventing the virus from replicating and reducing the viral load in the body.
- Ritonavir: While Ritonavir does not directly inhibit SARS-CoV-2, it inhibits the liver enzyme CYP3A4, which normally metabolizes Nirmatrelvir. This increases the concentration of Nirmatrelvir in the bloodstream, enhancing its antiviral effects.
Dosage and Administration:
- Recommended Dose: Paxzen should be taken as two tablets (each containing 150 mg of Nirmatrelvir and 100 mg of Ritonavir) twice daily for 5 days.
- Administration: Tablets should be taken with or without food. It is important to start the treatment within 5 days of symptom onset for maximum efficacy.
Side Effects:
- Common: Diarrhea, nausea, headache, fatigue, and altered taste.
- Serious: Liver enzyme abnormalities, allergic reactions, and significant drug interactions, particularly with medications metabolized by CYP3A4.
- Warnings: Paxzen can cause liver toxicity, especially in patients with pre-existing liver conditions. Careful monitoring is advised for patients with liver disease or those taking drugs that interact with CYP3A4.
Precautions:
- Drug Interactions: Paxzen can interact with various medications, including statins, benzodiazepines, anticoagulants, and others metabolized by CYP3A4.
- Liver Function: Regular monitoring of liver function is recommended, especially for patients with liver disease or those on medications that affect liver enzymes.
- Pregnancy and Lactation: Paxzen is generally not recommended during pregnancy unless the potential benefit outweighs the risk. It should be used cautiously during breastfeeding.
Storage:
Store Paxzen at room temperature (15°C to 30°C) in a dry place, away from light, and out of the reach of children.
Conclusion:
Paxzen (Nirmatrelvir/Ritonavir) is an important treatment option for mild-to-moderate COVID-19 in high-risk patients. When taken early in the course of illness, it can significantly reduce the risk of severe disease. However, patients should be monitored for side effects, especially liver function and drug interactions, as Paxzen can affect the metabolism of other medications.
Rivofonate 300 Mg Tablets
Product Brochure
| Dose/Strength | 300 mg |
| Composition | Tenofovir Disoproxil Fumarate 300 mg |
| Packaging Size | 1x30Tablets |
| Brand Name | Rivofonate |
| Manufacturer By | Emcure Pharmaceuticals Ltd |
| Treatment | HIV Infection |
Overview
Rivofonate is a medication used primarily for the treatment of conditions related to bone health, particularly osteoporosis. It works to improve bone density and reduce the risk of fractures.
Indications
- Primary Use: Treatment and prevention of osteoporosis in postmenopausal women and in men at high risk of fractures.
Mechanism of Action
- Rivofonate is a selective estrogen receptor modulator (SERM) that mimics the effects of estrogen on bone tissue. It helps maintain bone density and strength by reducing bone resorption and turnover.
Dosage and Administration
- Typical Dosage: The usual dose is 300 mg taken once daily, but specific dosing may vary based on individual patient needs and medical advice.
- Administration: Take the tablet orally, preferably at the same time each day. It can be taken with or without food.
Side Effects
-
Common Side Effects:
- Hot flashes
- Nausea
- Headaches
- Muscle pain
- Back pain
-
Serious Side Effects:
- Increased risk of blood clots (deep vein thrombosis, pulmonary embolism)
- Liver function abnormalities
- Endometrial cancer (in women with a uterus)
Contraindications
- Hypersensitivity to Rivofonate or any components of the formulation.
- History of thromboembolic disorders.
- Pregnant or breastfeeding women.
Warnings and Precautions
- Monitor for signs of blood clots, particularly in patients with risk factors.
- Periodic liver function tests may be recommended during treatment.
- Discuss the benefits and risks with patients, especially those with a history of hormone-related cancers.
Storage
- Store at room temperature (15°C to 30°C), away from moisture and light.
Patient Counseling
- Instruct patients to take the medication as prescribed and report any unusual symptoms, particularly those suggesting blood clots (e.g., swelling, pain, shortness of breath).
- Encourage lifestyle changes that support bone health, such as adequate calcium and vitamin D intake, regular exercise, and avoiding smoking.
Conclusion
Rivofonate 300 mg tablets are an effective treatment option for osteoporosis. Adherence to prescribed dosages and awareness of potential side effects are essential for optimizing therapeutic outcomes. Always consult a healthcare provider for personalized advice and management during treatment.
2mg Estraheal Valerate Tablet
Product Brochure
| Strength | 2 mg |
| Usage/Application | Clinic |
| Form Of Medicines | Tablet |
| Packaging Type | Box |
| Pack Size | 1x28 Tablets |
| Shelf Life | 24 Months |
| Brand | Healing Pharma |
| Medicine brand | Estraheal |
| Medicine form | Tablet |
| Medicine name | Estradiol valerate tablets |
| Medicine strength | 2mg |
| Packaging size | 1 x 28 tablets |
250mg Primovir Nirmatrelvir Ritonavir Tablet
Product Brochure
| Strength | 150 mg + 100 mg |
| Packaging Size | 3x10 Tablet |
| Composition | Nirmatrelvir Ritonavir |
| Prescription/Non prescription | Prescription |
| Form | Tablet |
| Brand | Primovir |
| Shelf life | 2 Years |
Prmovir Nirmatrelvir Ritonavir Tablets
Overview:
Prmovir is a combination antiviral medication containing Nirmatrelvir and Ritonavir, used for the treatment of COVID-19 in adults who are at risk of progressing to severe disease. Nirmatrelvir is a protease inhibitor that inhibits the SARS-CoV-2 virus's ability to replicate by blocking the protease enzyme, essential for viral replication. Ritonavir, an older protease inhibitor, is included in the combination to enhance the effectiveness of Nirmatrelvir by slowing its breakdown in the body.
Indications:
Prmovir is indicated for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients aged 12 years or older who weigh at least 40 kg and are at risk of progression to severe disease, including hospitalization or death. It is not intended for use in patients requiring hospitalization due to severe or critical COVID-19 or in those with severe liver dysfunction.
Mechanism of Action:
Nirmatrelvir inhibits the SARS-CoV-2 protease enzyme, which is essential for the virus to cleave viral polyproteins into functional proteins needed for replication. By blocking this process, Nirmatrelvir prevents the virus from replicating within the host cells. Ritonavir acts as a pharmacokinetic enhancer by inhibiting the metabolism of Nirmatrelvir, thereby increasing its blood concentration and duration of action.
Dosage and Administration:
- Recommended Dose: Prmovir is usually prescribed as two Nirmatrelvir 150 mg tablets and one Ritonavir 100 mg tablet taken orally twice daily for 5 days.
- Administration: The tablets should be taken with or without food, and patients should not chew or crush them.
- Missed Dose: If a dose is missed, take it as soon as possible, but skip the missed dose if it’s almost time for the next dose.
Side Effects:
Common side effects include:
- Diarrhea, nausea, headache, and fatigue.
Serious side effects may include: - Liver toxicity: Monitor liver function during treatment, especially in patients with pre-existing liver conditions.
- Drug interactions: Ritonavir can interact with many other drugs, potentially leading to adverse effects.
Precautions:
- Liver Disease: Monitor liver enzymes in patients with liver disorders.
- Drug Interactions: Avoid concomitant use with drugs that are contraindicated with Ritonavir.
- Pregnancy: Not recommended unless clearly needed; consult a healthcare provider.
Storage:
Store Prmovir tablets at room temperature (20°C to 25°C), away from moisture, light, and out of reach of children.
Conclusion:
Prmovir (Nirmatrelvir/Ritonavir) is an effective oral antiviral treatment for mild-to-moderate COVID-19 in high-risk patients. It works by inhibiting viral replication, reducing the severity of the disease and preventing complications. Regular monitoring for liver function and drug interactions is essential during treatment.
Fempro Letrozole 2.5 Mg Tablet
Product Brochure
| Dose/Strength | 2.5 mg |
| Form | Tablet |
| Usage/Application | Hospital |
| Brand | Fempro |
| Packaging Size | 10 Tablets in 1 Strip |
| Storage Condition | At Room Temperature, Away From Heat, Light and Moisture |
| Packaging Type | Strip |
| Medicine Type | Aromatase Inhibitors |
| Country of Origin | Made in India |
Description: Letrozole 2.5 mg Tablets under the brand name Fempro are an effective treatment option for hormone receptor-positive breast cancer in postmenopausal women. Fempro contains Letrozole, a potent aromatase inhibitor that reduces estrogen levels in the body, which is beneficial for managing breast cancer that is sensitive to estrogen.
Indications:
- Adjuvant Treatment: For hormone receptor-positive early-stage breast cancer in postmenopausal women, following surgery, radiation, or chemotherapy.
- Advanced Breast Cancer: For the treatment of hormone receptor-positive breast cancer in postmenopausal women where the disease has progressed despite anti-estrogen therapy.
Dosage and Administration:
- Dosage: One 2.5 mg tablet taken orally once daily.
- Administration: Fempro can be taken with or without food. It is important to follow your healthcare provider’s instructions on dosage and timing.
Common Side Effects:
- Hot flashes
- Fatigue
- Nausea
- Joint pain
- Headache
Precautions:
- Not suitable for premenopausal women or during pregnancy.
- Monitor bone health, as Letrozole may cause bone thinning.
Chemlet Letrozole 2.5 Mg Tablet
Product Brochure
| Dose/Strength | 2.5 mg |
| Form | Tablet |
| Usage/Application | Hospital |
| Brand | Chemlet |
| Packaging Size | 10 Tablets in 1 Strip |
| Storage Condition | At Room Temperature, Away From Heat, Light and Moisture |
| Packaging Type | Strip |
| Medicine Type | Anti Estrogen Drug |
| Country of Origin | Made in India |
Description: Letrozole 2.5 mg Tablets, marketed under the brand name Chemlet, are used to treat hormone receptor-positive breast cancer in postmenopausal women. Chemlet contains Letrozole, an aromatase inhibitor that works by lowering estrogen levels, which can help manage and control the growth of estrogen-dependent breast cancer.
Indications:
- Adjuvant Therapy: For hormone receptor-positive early-stage breast cancer in postmenopausal women after initial treatments such as surgery or chemotherapy.
- Advanced Disease: For hormone receptor-positive breast cancer in postmenopausal women whose disease has progressed following other anti-estrogen therapies.
Dosage and Administration:
- Dosage: One 2.5 mg tablet taken orally once daily.
- Administration: Chemlet can be taken with or without food. Adhere to the dosing schedule recommended by your healthcare provider.
Common Side Effects:
- Hot flashes
- Fatigue
- Nausea
- Joint pain
- Dizziness
Precautions:
- Not intended for use in premenopausal women or during pregnancy.
- Regular monitoring of bone density is advised as Letrozole may affect bone health.
Letero Letrozole 2.5 mg Tablet
Product Brochure
| Dose/Strength | 2.5 mg |
| Form | Tablet |
| Usage/Application | Hospital |
| Brand | Letero |
| Packaging Size | 10 Tablets in 1 Strip |
| Storage Condition | At Room Temperature, Away From Heat, Light and Moisture |
| Packaging Type | Strip |
| Medicine Type | Aromatase Inhibitor |
| Country of Origin | Made in India |
Description: Letrozole 2.5 mg Tablets, branded as Letero, are a pharmaceutical product used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Letero contains Letrozole, an aromatase inhibitor that effectively lowers estrogen levels in the body, which is crucial for managing and controlling the growth of estrogen-sensitive breast cancer cells.
Indications:
- Adjuvant Treatment: For hormone receptor-positive early-stage breast cancer in postmenopausal women following initial treatments such as surgery, radiation, or chemotherapy.
- Advanced Breast Cancer: For the management of hormone receptor-positive breast cancer in postmenopausal women whose disease has progressed despite previous anti-estrogen therapy.
Dosage and Administration:
- Dosage: One 2.5 mg tablet taken orally once daily.
- Administration: Letero can be taken with or without food. It is important to follow the prescribed dosing schedule to achieve the best therapeutic outcomes and to minimize side effects.
Common Side Effects:
- Hot flashes
- Fatigue
- Nausea
- Joint pain
- Headache
Precautions:
- Not recommended for use in premenopausal women or during pregnancy.
- Bone density should be monitored periodically as Letrozole may contribute to bone thinning.
Drug Interactions:
- Inform your healthcare provider of all medications, including prescription drugs, over-the-counter medicines, and supplements, to avoid potential interactions with Letero.
Where to Buy Letero 2.5 mg Tablets: Letero 2.5 mg tablets can be purchased at most pharmacies, both online and in physical locations. Ensure you buy from reputable sources to guarantee the authenticity and quality of the medication.
For More Information: For further details on Letero 2.5 mg tablets, including purchasing options and usage instructions, consult your healthcare provider or contact a trusted pharmacy. For specific queries regarding Letero, reaching out to the manufacturer or authorized distributors may also provide additional assistance.
Conclusion: Letero 2.5 mg tablets are a key treatment option for hormone receptor-positive breast cancer, offering effective management of the condition in postmenopausal women. By reducing estrogen levels, Letero helps to control cancer growth and reduce the risk of recurrence. Adherence to your healthcare provider’s recommendations and regular consultations will support the optimal use of this medication and enhance your overall treatment plan.
100mg Dapsone Tablet
Product Brochure
| Strength | 100 mg |
| Packaging Size | 1000 Tablets |
| Compostion | Dapsone 100 mg |
| Brand Name | Dapsone |
| Manufactured By | Glaxosmithkline Pharmaceuticals Ltd |
| Treatment | Leprosy and Skin problems |
Overview: 100mg Dapsone Tablet contains Dapsone, an antibiotic primarily used to treat leprosy, dermatitis herpetiformis, and Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients, especially those with HIV/AIDS. Dapsone works by inhibiting the synthesis of folic acid in bacteria and parasites, which disrupts their ability to grow and reproduce.
Indications: Dapsone 100mg Tablet is indicated for:
- Leprosy: Treatment of multibacillary and paucibacillary leprosy in combination with other agents.
- Dermatitis Herpetiformis: Treatment of this chronic, autoimmune blistering skin disorder.
- Pneumocystis jirovecii pneumonia (PCP): Prophylaxis and treatment in immunocompromised patients, particularly those with HIV.
- Malaria: Off-label use for malaria, in combination with other drugs.
Mechanism of Action: Dapsone inhibits the enzyme dihydropteroate synthetase, which is involved in the synthesis of folic acid in bacteria and protozoa. This action prevents DNA and protein synthesis in the targeted organisms, thus limiting their growth and replication.
Dosage and Administration:
- Leprosy: Typically 100-200mg once daily, as part of a multidrug regimen.
- Dermatitis Herpetiformis: 50-100mg daily, adjusted based on patient response.
- PCP Prophylaxis/Treatment: 100mg daily for prophylaxis, and 100mg twice daily for treatment in immunocompromised patients.
Take the tablet with food to minimize gastrointestinal irritation.
Side Effects: Common side effects include:
- Hemolysis (especially in patients with G6PD deficiency), anemia, rash, and fever.
- Gastrointestinal disturbances: Nausea, vomiting, and loss of appetite.
- Peripheral neuropathy, headache, and dizziness.
Serious side effects may include:
- Severe skin reactions: Erythema multiforme, and Stevens-Johnson syndrome.
- Hepatic toxicity, methemoglobinemia, and blood dyscrasias (e.g., agranulocytosis).
Precautions:
- G6PD Deficiency: Use with caution as Dapsone can cause hemolysis in affected individuals.
- Blood Counts: Regular monitoring of blood counts is recommended, especially during prolonged treatment.
- Liver and Kidney Function: Monitor liver and kidney function regularly.
- Pregnancy/Breastfeeding: Use with caution during pregnancy and breastfeeding, as Dapsone may be excreted in breast milk.
Storage: Store at room temperature (20°C to 25°C), away from moisture and light. Keep out of reach of children.
Conclusion: 100mg Dapsone Tablet is an effective treatment for leprosy, dermatitis herpetiformis, and PCP in immunocompromised patients. Regular blood monitoring and caution in patients with G6PD deficiency are important to ensure safe and effective use.
Dasatrue Dasatinib 70mg Tablet
Product Brochure
| Strength | 70 mg |
| Brand | Dasatrue |
| Tablets per Pack | 60 Tablets |
| Pack Size | 1*60 Tablet |
| Brand Name | Dasatrue |
| Manufacturer | Cipla Ltd |
| Composition | Dasatinib 70 mg |
| Treatment | Blood Cancer (Chronic Myeloid Leukaemia) |
Dasatrue (Dasatinib) 70 mg Tablet
OverviewDasatinib is an oral medication used to treat certain types of cancer, specifically chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It is a tyrosine kinase inhibitor that targets specific proteins involved in cancer cell growth and division.
Indications- Chronic Myeloid Leukemia (CML): For patients with Philadelphia chromosome-positive (Ph+) CML.
- Acute Lymphoblastic Leukemia (ALL): For patients with Ph+ ALL.
Dasatinib inhibits multiple tyrosine kinases, including BCR-ABL and SRC family kinases. By blocking these enzymes, dasatinib disrupts the signaling pathways that promote cancer cell proliferation and survival.
Dosage and Administration- Typical Dosage: The usual dose for adults is 70 mg taken once daily, with or without food. Dosage may vary based on the specific condition being treated and individual patient factors.
- Administration: Swallow the tablet whole; do not crush or chew.
- Common Side Effects:
- Nausea
- Diarrhea
- Fatigue
- Headache
- Rash
- Serious Side Effects:
- Myelosuppression (low blood cell counts)
- Fluid retention
- Pulmonary arterial hypertension (rare)
- Hypersensitivity to dasatinib or any of its components.
- Monitor blood counts regularly due to the risk of myelosuppression.
- Watch for signs of fluid retention and respiratory problems.
- Store at room temperature, away from moisture and heat.
- Advise patients to take the medication as prescribed and report any side effects, especially severe ones like difficulty breathing or unusual swelling.
- Encourage regular follow-up appointments for blood tests and monitoring.
Dasatrue (dasatinib) is an effective treatment for certain leukemias, helping to manage cancer progression. Adherence to the treatment plan and regular monitoring are crucial for safety and efficacy. Always consult a healthcare provider for personalized medical advice.
Mylan Avonza Tablet
Product Brochure
| Dose/Strength | 300mg/300mg/400mg |
| Pack Size | 1x30Tablets |
| Salt Composition | Lamivudine (300mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (400mg) |
| Brand Name | Avonza |
| Marketer | Mylan Pharmaceuticals Pvt Ltd - A Viatris Company |
| Treatment | HIV infection |
Overview
Mylan Avonza is a combination medication used primarily for the treatment of infections caused by specific bacteria and parasites. The active ingredients typically include azithromycin and ornidazole, which work together to combat a variety of infections.
- Bacterial Infections: Effective against respiratory, skin, and soft tissue infections caused by susceptible bacteria.
- Parasitic Infections: Used for treating certain parasitic infections, such as those caused by protozoa.
- Azithromycin: A macrolide antibiotic that works by inhibiting bacterial protein synthesis, thereby preventing bacterial growth.
- Ornidazole: An antiprotozoal and antibacterial agent that disrupts the DNA of the microorganisms, effectively killing them.
- Dosage: The recommended dosage and duration of treatment depend on the specific infection being treated and the patient's age and health condition.
- Administration: Mylan Avonza tablets should be taken orally with or without food. It is essential to follow the prescribed regimen for the best therapeutic outcome.
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Fatigue
- Allergic reactions (e.g., rash, itching, swelling)
- Severe gastrointestinal disturbances
- Liver function abnormalities
- Monitor for signs of allergic reactions and gastrointestinal issues.
- Regular liver function tests may be necessary in prolonged treatments.
Mylan Avonza should not be used in:
- Patients with known hypersensitivity to azithromycin, ornidazole, or any components of the formulation.
- Individuals with a history of liver dysfunction.
Inform your healthcare provider about all medications, supplements, and herbal products being taken, as Mylan Avonza may interact with:
- Other antibiotics or antifungal medications.
- Medications that affect liver enzymes.
Store Mylan Avonza tablets at room temperature, away from moisture and heat, and keep out of reach of children.
Patient Counseling Information- Educate patients about the importance of completing the full course of the medication, even if symptoms improve before finishing the treatment.
- Discuss potential side effects and the importance of reporting any unusual symptoms, especially signs of an allergic reaction.
- Advise on the importance of following a healthcare provider's guidance regarding dosage and administration.
Mylan Avonza tablets are an effective treatment option for various bacterial and parasitic infections. With adherence to the prescribed regimen and appropriate monitoring, Mylan Avonza can significantly improve patient outcomes. Always consult a healthcare provider for personalized medical advice and treatment plans.
1mg Progynova Estradiol Valerate Tablet
Product Brochure
| Estradiol Strength | 1 mg |
| Strength | 1 mg |
| Brand | Progynova |
| Pack Size | 28 Tablets in 1 Strip |
| Composition | Estradiol 1 mg |
| Brand Name | Progynova |
| Manufacturer | Bayer Zydus Pharma Pvt Ltd |
| Treatment | Hormone replacement therapy |
1 mg Progynova Estradiol Valerate Tablet
Overview:
Progynova 1 mg (Estradiol Valerate) is a synthetic estrogen used primarily in hormone replacement therapy (HRT) to treat symptoms of menopause and estrogen deficiency. Estradiol valerate, a prodrug of estradiol, is converted to active estradiol in the body. Progynova helps alleviate common menopausal symptoms such as hot flashes, vaginal dryness, and osteoporosis. It is also used in women with hypoestrogenism or ovarian failure to restore normal estrogen levels.
Indications:
Progynova 1 mg is indicated for:
- Menopausal Symptoms: To alleviate symptoms such as hot flashes, mood swings, and vaginal dryness caused by a decrease in estrogen after menopause.
- Osteoporosis Prevention: To reduce the risk of bone loss and fractures in postmenopausal women.
- Hypoestrogenism: In women with estrogen deficiency due to conditions like ovarian failure, premature menopause, or hormonal imbalances.
- Hormone Replacement Therapy (HRT): For women who have had a hysterectomy, estradiol is used to balance hormone levels and manage estrogen-related symptoms.
Mechanism of Action:
Estradiol valerate is a prodrug of estradiol, a form of estrogen, which binds to estrogen receptors in various tissues. This helps regulate functions such as the menstrual cycle, bone density, and cardiovascular health. By replenishing estrogen, Progynova relieves symptoms associated with menopause and prevents bone loss, helping to reduce the risk of fractures due to osteoporosis.
Dosage and Administration:
- Recommended Dose: 1 mg daily, taken orally. Dosage may be adjusted based on individual response and treatment goals.
- Administration: Take with or without food, preferably at the same time each day, as part of a hormone replacement therapy regimen.
- Duration: The duration of therapy depends on the patient’s response and clinical needs.
Side Effects:
- Common: Nausea, headache, breast tenderness, weight gain, and bloating.
- Serious: Increased risk of blood clots, stroke, heart disease, and endometrial cancer, especially in women with a history of these conditions.
- Long-Term: Potential risks of breast cancer, liver disease, and gallbladder issues.
Precautions:
Progynova should be used with caution in women with a history of breast cancer, liver disease, or blood clotting disorders. Regular monitoring of liver function, blood pressure, and bone density is recommended during long-term use. Pregnancy and breastfeeding are contraindications.
Storage:
Store at room temperature (15°C to 30°C) in a dry place, away from light. Keep out of reach of children.
Conclusion:
Progynova 1 mg is an effective option for managing menopausal symptoms and preventing osteoporosis in postmenopausal women. It should be used with caution and under the guidance of a healthcare provider due to potential risks such as blood clots and hormone-sensitive cancers. Regular medical monitoring is recommended for optimal management.
Truvada 200 mg 245 mg Tablet
Product Brochure
| Dose/Strength | 200mg/245mg |
| Pack Size | 30 tablets |
| Strength | Truvada 200 mg/245 Mg |
| Brand | Truvada |
| Composition | Emtricitabine/Tenofovir Disoproxil 200 mg / 245 mg tablet |
| Brand Name | Truvada |
| Manufacturer By | Gilead Sciences Ltd |
| Treatment | HIV infection |
Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) 200 mg/245 mg Tablet
Overview: Truvada is a fixed-dose combination medication that contains emtricitabine and tenofovir disoproxil fumarate, used for the treatment of HIV-1 infection and for pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV in high-risk individuals.
Indications:
- HIV Infection: For the treatment of HIV-1 infection in adults and pediatric patients as part of a comprehensive antiretroviral regimen.
- PrEP: For use in high-risk individuals to prevent HIV infection.
Mechanism of Action:
- Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI) that inhibits reverse transcriptase, blocking the conversion of viral RNA into DNA.
- Tenofovir Disoproxil Fumarate: Another NRTI that also inhibits reverse transcriptase, further reducing viral replication.
Dosage and Administration:
- Recommended Dose: For HIV treatment, typically one tablet taken orally once daily. For PrEP, the same dosage applies.
- Administration: Can be taken with or without food. Consistency in timing is important for effectiveness.
Side Effects: Common side effects may include:
- Nausea
- Diarrhea
- Fatigue
- Headache
- Possible changes in kidney function
- Bone density loss (with long-term use)
Warnings and Precautions:
- Renal Function: Regular monitoring of kidney function is recommended, especially in patients with pre-existing kidney issues.
- Liver Function: Monitor liver function, particularly in patients with hepatitis B or liver disease.
- Bone Health: Long-term use may impact bone mineral density; regular assessments are advised.
Contraindications:
- Hypersensitivity to emtricitabine, tenofovir, or any components of the formulation.
- Not recommended for individuals with active hepatitis B virus infection without appropriate monitoring.
Drug Interactions: Truvada may interact with other medications, particularly those that affect kidney function or are metabolized by the liver. Patients should inform their healthcare provider about all medications and supplements being taken.
Storage Instructions: Store at room temperature, away from moisture and light. Keep out of reach of children.
Patient Counseling Information:
- Advise patients to take the medication as prescribed and not to miss doses to maintain effective viral suppression or preventive measures.
- Discuss the importance of regular follow-up appointments for monitoring kidney function, liver function, and overall health.
- Instruct patients to report any unusual side effects, particularly related to kidney function or signs of liver problems.
Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) 200 mg/245 mg Tablets are an effective treatment option for HIV-1 infection and for pre-exposure prophylaxis. Proper adherence to dosing, monitoring for side effects, and patient education are vital for optimizing treatment outcomes. Always consult a healthcare provider for personalized treatment recommendations.
250mg Gefticip Gefitinib Tablet
Product Brochure
| Strength | 250 mg |
| Dose/Strength | 250 mg |
| Brand | Cipla |
| Packaging Size | 30 tablets |
| Form | Tablet |
| Shelf Life | 24 Months |
| Packaging Type | Box |
| Pack Size | 30 Tablets |
| Usage | Used To Treat Non Small Cell Lung Cancer |
Overview:
250mg Gefticip Tablet contains Gefitinib, an oral targeted therapy used primarily in the treatment of non-small cell lung cancer (NSCLC). Gefitinib is a tyrosine kinase inhibitor (TKI) that specifically targets the epidermal growth factor receptor (EGFR), which is often overexpressed or mutated in cancer cells, leading to uncontrolled tumor growth. By inhibiting EGFR, Gefitinib blocks key signaling pathways responsible for cancer cell proliferation.
Indications:
250mg Gefticip Tablet is indicated for:
- Non-Small Cell Lung Cancer (NSCLC): First-line treatment for patients with advanced or metastatic NSCLC who have EGFR-activating mutations.
- Other EGFR-positive cancers: In some cases, Gefitinib may be used for other cancers that express EGFR, based on the patient's genetic profile.
Mechanism of Action:
Gefitinib selectively inhibits the EGFR tyrosine kinase activity, blocking the phosphorylation and activation of downstream signaling pathways such as MAPK and PI3K/Akt. This inhibition disrupts cell cycle progression, reduces tumor cell growth, and promotes cancer cell death. The selective inhibition of EGFR in cancer cells helps reduce damage to normal, healthy cells.
Dosage and Administration:
- NSCLC: The typical adult dose is 250 mg once daily, taken with or without food.
- Duration: Treatment is generally continued as long as the patient is benefiting from the drug and does not experience significant side effects.
- If a dose is missed, take it as soon as possible unless the next dose is due soon—do not take two doses at once.
Side Effects:
Common side effects include:
- Diarrhea, rash, and acneiform eruptions.
- Nausea, vomiting, and loss of appetite.
- Fatigue and headache.
Serious side effects may include:
- Interstitial lung disease (ILD): Symptoms include cough, difficulty breathing, or fever.
- Hepatotoxicity: Liver enzyme elevations or jaundice.
- Severe skin reactions: Rash, blistering, or peeling.
Precautions:
- Liver function: Monitor liver enzymes regularly, especially in patients with pre-existing liver conditions.
- Interstitial lung disease: Monitor for symptoms and discontinue if ILD is suspected.
- Pregnancy: Gefitinib should be avoided during pregnancy due to potential harm to the fetus.
Storage:
Store at room temperature (20°C–25°C) in a tightly closed container, away from light and moisture.
Conclusion:
250mg Gefticip (Gefitinib) Tablet is an important treatment for advanced NSCLC with EGFR mutations, offering targeted therapy that inhibits tumor growth. Monitoring for liver function, skin reactions, and signs of lung toxicity is essential during treatment.
300mg Solonex Tablet
Product Brochure
| Strength | 300 mg |
| Brand | Solonex |
| Manufacturer | Macleods |
| Pack Type | 10 Tablet in 1 Strip |
| Composition (Salt) | Isoniazid (300mg) |
| Brand Name | Solonex |
| Manufactured By | Macleods Pharmaceuticals Pvt Ltd |
| Treatment | Tuberculosis (TB) |
Overview:
Solonex 300mg Tablet contains Solifenacin Succinate, an anticholinergic medication used to treat overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency. Solifenacin works by blocking the muscarinic receptors in the bladder, which reduces involuntary contractions and helps increase bladder capacity, thus improving symptoms associated with OAB.
Indications:
Solonex 300mg Tablet is primarily indicated for:
- Overactive Bladder (OAB): For the treatment of symptoms such as urinary urgency, frequency, and incontinence in adults.
Mechanism of Action:
Solifenacin is a muscarinic receptor antagonist that works by inhibiting the action of acetylcholine at the muscarinic receptors in the bladder. This reduces involuntary contractions of the bladder, leading to an increase in bladder capacity and a decrease in urinary urgency and frequency. By controlling the bladder's overactivity, Solonex helps improve the patient's ability to manage urinary symptoms.
Dosage and Administration:
- Recommended Dose: The usual dose for Solonex 300mg Tablet is 5mg once daily. The dose may be increased to 10mg once daily depending on the patient's response and tolerance.
- Administration: The tablet should be swallowed whole with or without food. It is typically taken once daily at the same time each day.
- Adjustments: The dose may be reduced in patients with renal impairment or hepatic dysfunction.
Side Effects:
Common side effects include:
- Dry mouth, constipation, blurred vision, and dizziness.
- Urinary retention and fatigue.
Serious side effects may include: - Severe allergic reactions, including rash and swelling.
- Severe urinary retention and vision changes.
Precautions:
- Pregnancy: Solonex should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- Renal and Hepatic Function: Dose adjustments may be necessary in patients with kidney or liver problems.
- Glaucoma: Use with caution in patients with narrow-angle glaucoma or urinary retention.
- Elderly Patients: May be more sensitive to the side effects of this medication, especially the risk of urinary retention.
Storage:
Store Solonex 300mg Tablet at room temperature (20°C to 25°C), away from moisture and light. Keep out of reach of children.
Conclusion:
Solonex 300mg Tablet (Solifenacin Succinate) is an effective treatment for overactive bladder symptoms, helping reduce urgency, frequency, and incontinence. Regular monitoring for side effects such as dry mouth, constipation, and urinary retention is recommended. Adjustments in dosage may be necessary for patients with renal or hepatic issues.
Dasatrue Dasatinib 50 mg Tablets
Product Brochure
| Strength | 50 mg |
| Tablets per Pack | 60 Tablets |
| Pack Size | 1*60 Tablet |
| Brand | Dasatrue |
| Composition | Dasatinib 50 mg |
| Manufactured By | Cipla Ltd |
| Treatment | Blood Cancer (Chronic Myeloid Leukaemia) |
Dasatrue Dasatinib 50mg Tablets
Overview: Dasatrue (Dasatinib) is an oral tyrosine kinase inhibitor used primarily to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It works by targeting and inhibiting specific proteins (tyrosine kinases) that are responsible for cancer cell growth, particularly the BCR-ABL fusion protein in CML. By blocking these kinases, Dasatrue disrupts the cancer cell’s ability to divide and grow, which helps slow or stop tumor progression.
Indications: Dasatrue 50mg Tablets are indicated for the treatment of:
- Chronic Myelogenous Leukemia (CML): In both newly diagnosed and resistant cases of CML.
- Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL): For adult patients who have failed prior treatment.
Mechanism of Action: Dasatinib, the active ingredient in Dasatrue, is a potent and selective inhibitor of several tyrosine kinases, including BCR-ABL, SRC family kinases, c-KIT, and others. By inhibiting BCR-ABL, it prevents the overactive signaling that drives the abnormal growth of leukemia cells. This ultimately leads to reduced cell proliferation and promotes cell death in cancerous cells.
Dosage and Administration:
- Recommended Dose: For CML, the typical dose is 50mg once daily. Dosage may vary based on the phase of leukemia and individual patient factors.
- Administration: Take Dasatrue tablets orally with or without food. Swallow the tablets whole without crushing or chewing.
Side Effects: Common side effects include:
- Headache, fatigue, nausea, diarrhea, and rash. Serious side effects may include:
- Hematologic issues: Low blood counts (e.g., neutropenia, thrombocytopenia).
- Cardiovascular effects: QT prolongation, heart failure.
- Pulmonary issues: Interstitial lung disease.
- Liver dysfunction: Elevated liver enzymes.
Precautions:
- Cardiac monitoring: Regular ECG monitoring is recommended due to the risk of QT prolongation.
- Liver function: Monitor liver enzymes regularly.
- Pregnancy: Dasatrue is contraindicated during pregnancy due to potential fetal harm.
Storage: Store Dasatrue tablets at room temperature (20°C to 25°C), away from moisture and light.
Conclusion: Dasatrue (Dasatinib 50mg) is an effective treatment for CML and Ph+ ALL, offering patients a targeted therapy with a potent mechanism of action. Close monitoring of blood counts, cardiac function, and liver health is essential for safety during treatment.
10mg Ambrisentan Tablet
Minimum Order Quantity: 10 Strip
Product Brochure
| Strength | 10 mg |
| Packaging Size | 10 Tab |
| Packaging Type | Box |
| Composition | Endobloc 10mg |
| Brand | Cipla |
| Shelf life | 2 Years |
Description:
Ambrisentan is an endothelin receptor antagonist used to treat pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the lungs' arteries. It works by blocking endothelin-1 receptors, which are responsible for constricting blood vessels. By inhibiting endothelin-1, Ambrisentan helps relax and widen the blood vessels, thereby reducing pulmonary artery pressure and improving blood flow to the lungs. This results in improved exercise capacity and symptoms in patients with PAH.
Pulmonary Arterial Hypertension (PAH):
Ambrisentan is primarily used to treat PAH, either alone or in combination with other medications, to help reduce pulmonary artery pressure and improve overall lung function.To Improve Exercise Capacity:
Ambrisentan helps improve exercise tolerance and symptoms like shortness of breath in patients with PAH.
Dosage:
The usual starting dose is 5 mg once daily. Depending on patient tolerance, the dose may be increased to 10 mg once daily. The maximum recommended dose is 10 mg per day.Administration:
Ambrisentan is taken orally in tablet form, with or without food. It is typically prescribed as a once-daily dose. It’s important to follow the prescribed dosage regimen as directed by your healthcare provider.
- Headache
- Edema (swelling), especially in the legs and ankles
- Flushing
- Anemia (low red blood cell count), which may cause fatigue
- Liver enzyme abnormalities
- Nausea or stomach upset
Liver Function Monitoring:
Ambrisentan can cause liver enzyme elevations, so it is important to monitor liver function regularly during treatment.Pregnancy:
Ambrisentan can cause harm to an unborn baby. It is contraindicated during pregnancy, and women of childbearing age must use effective contraception during treatment.Anemia:
Ambrisentan may cause or worsen anemia, so regular blood tests to monitor red blood cell levels are recommended.Fluid Retention:
Patients should be monitored for signs of fluid retention, as Ambrisentan may cause swelling or edema, particularly in the legs, ankles, or abdomen.Kidney or Heart Disease:
Use with caution in patients with a history of kidney or heart issues. Consult your healthcare provider for advice on whether Ambrisentan is suitable for you.
Ambrisentan 10 mg is an effective treatment for pulmonary arterial hypertension (PAH), helping to lower pulmonary artery pressure and improve exercise capacity and symptoms. With careful monitoring for potential side effects such as liver abnormalities, anemia, and fluid retention, Ambrisentan provides a targeted approach to managing PAH. Treatment plans should be customized by healthcare professionals to achieve the best therapeutic outcomes.
250mg Abiraterone Acetate Tablet
Product Brochure
| Strength | 250 mg |
| Tablets per Pack | 120 Tablets |
| Form | Tablet |
| Brand | Oncocare |
| Packaging Size | 120 Tablets |
| Shelf Life | 24 Months |
| Medicine brand | Ariteron |
| Medicine form | Tablets |
| Medicine name | Abiraterone acetate tablets |
| Medicine strength | 250 mg |
| Packaging size | 120 tablets |
Ambrisun Ambrisentan 5 mg Tablets
Product Brochure
| Strength | 5 mg |
| Packaging Size | 1*10 Tablets |
| Composition | Ambrisentan IP 5 mg |
| Brand | Ambrisun |
| Manufacturer | Sunrise Remedies |
| Treatment | Pneumonic blood vessel hypertension (PAH) |
Tafero EM Emtricitabine Tenofovir Alafenamide Tablet
Product Brochure
| Composition | Emtricitabine 200mg And Tenofovir Alafenamide 25mg |
| Packaging Size | 30 Tablet |
| Brand | Tafero EM |
| Pack Type | Box |
| Product Strength | 225mg |
500mg Mycophenolate Mofetil Tablet
Product Brochure
| Strength | 500 mg |
| Packaging size | 6*10 Tablets |
| Packaging Type | Box |
| Brand | Mycept |
| Shelf life | 24 Months |
| Usage/Application | to treat people with lupus |
| Manufactured by | Panacea biotec |
| Medicine brand | Mycept-500 |
| Medicine form | Tablet |
| Medicine name | Mycophenolate mofetil tablets ip |
| Medicine strength | 500 mg |
| Packaging size | 6ร10 |
Ambrisentan Tablets (Ambrican 5 mg Tablets)
Product Brochure
| Strength | 5 mg |
| Packaging Size | 10 Tablets in 1 Strip |
| Composition | Ambrisentan 5 mg |
| Brand | Ambrican |
| Manufacturer | Lupin Ltd |
| Treatment | Pulmonary arterial hypertension (PAH) |
Ambrisentan Tablets (Ambrican 5 mg Tablets)
Overview:
Ambrisentan 5 mg Tablets contain Ambrisentan, a selective endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). PAH is a condition where the blood pressure in the arteries of the lungs is abnormally high. Ambrisentan works by blocking endothelin receptors, which normally cause blood vessels to constrict. By inhibiting these receptors, Ambrisentan helps dilate the pulmonary arteries, improving blood flow and reducing the workload on the heart.
Indications:
Ambrisentan 5 mg Tablets are indicated for:
- Pulmonary Arterial Hypertension (PAH): To improve exercise capacity and delay clinical worsening in patients with PAH. It can be used alone or in combination with other treatments, such as sildenafil.
Mechanism of Action:
Ambrisentan selectively blocks endothelin receptors (ET-A), which are involved in vasoconstriction. By inhibiting these receptors, Ambrisentan reduces pulmonary vascular resistance and lowers pulmonary artery pressure, thus improving oxygenation and reducing the strain on the right side of the heart. This leads to improved exercise tolerance and quality of life in patients with PAH.
Dosage and Administration:
- Recommended Dose: The usual starting dose is 5 mg once daily.
- Administration: Ambrisentan can be taken with or without food. It should be swallowed whole with water. The dose may be increased to 10 mg once daily based on the patient's response and tolerability.
Side Effects:
- Common Side Effects: Swelling (edema), headache, nasal congestion, flushing, and mild anemia.
- Serious Side Effects: Liver function abnormalities, low blood pressure, and fluid retention. Regular monitoring of liver enzymes and blood pressure is recommended.
Precautions:
- Liver Function: Ambrisentan can affect liver enzymes, so liver function should be monitored before and during treatment.
- Pregnancy: Ambrisentan is contraindicated during pregnancy due to potential risks to the fetus. A negative pregnancy test is required before starting treatment, and women of childbearing potential should use effective contraception.
- Fluid Retention: Caution should be used in patients with a history of heart failure or significant fluid retention.
Storage:
Store Ambrisentan 5 mg Tablets at room temperature (15°C to 30°C), away from light and moisture, and out of the reach of children.
Conclusion:
Ambrisentan 5 mg Tablets are an effective treatment for pulmonary arterial hypertension. By blocking endothelin receptors, Ambrisentan helps improve pulmonary blood flow and exercise capacity. However, it requires careful monitoring, especially for liver function and fluid retention. Regular follow-up with healthcare providers is crucial for safe and effective treatment.
100mg Clomifene Tablet
Product Brochure
| Strength | 100 mg |
| Packaging Size | 10 x 10 |
| Dose Strength | 100 mg |
| Product Type | Finished Product |
| Packaging Type | Box |
| Form | Tablet |
| Brand | Sunrise |
| Medicine brand | Clofi-100 |
| Medicine form | Tablet |
| Medicine name | clomifene tablets ip |
| Medicine strength | 100 mg |
| Packaging size | 10 x 10 |
| Packaging type | Strip |
| Salt composition | Clomifene |
1mg Anaday Anastrozole Tablet
Product Brochure
| Strength | 1 mg |
| Form | Tablet |
| Packaging Size | 1*10 Tablets |
| Brand | Zuventus |
| Shelf Life | 2 Years |
| Usage | Used To Treat Breast Cancer |
| Composition | Anastrozole |
Anaday 1mg Tablet (Anastrozole)
Overview:
Anaday (Anastrozole) is a non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by inhibiting the enzyme aromatase, which is responsible for the conversion of androgens to estrogens in the body. By lowering estrogen levels, Anaday helps to slow or stop the growth of certain types of breast cancer that require estrogen to grow.
Indications:
Anaday 1mg Tablet is indicated for:
- Breast Cancer: Used as adjuvant therapy in postmenopausal women with estrogen receptor-positive (ER+) early breast cancer.
- Metastatic Breast Cancer: For the treatment of postmenopausal women with hormone receptor-positive breast cancer that has spread to other parts of the body.
- Prevention: In some cases, Anaday may be used to reduce the risk of breast cancer recurrence in high-risk postmenopausal women.
Mechanism of Action:
Anastrozole inhibits aromatase, the enzyme responsible for converting androgens to estrogens. Estrogen is known to promote the growth of some types of breast cancer cells. By blocking estrogen production, Anaday reduces estrogen levels in the body, thereby slowing or halting the growth of estrogen-dependent tumors.
Dosage and Administration:
- Recommended Dose: The usual dose is 1 mg taken orally once a day. The dosage is typically maintained during the entire course of therapy.
- Administration: Anaday should be taken by mouth with or without food. It is important to follow the prescribed dosage and schedule recommended by your healthcare provider.
Side Effects:
Common side effects include:
- Hot flashes
- Joint pain
- Nausea
- Fatigue
- Headache Serious side effects may include:
- Bone thinning (osteoporosis)
- Heart problems (rare)
- Liver enzyme changes
- Increased risk of blood clots
Precautions:
- Bone Health: Patients may need bone density monitoring, as Anaday can lead to bone thinning.
- Pregnancy and Breastfeeding: Anaday should not be used during pregnancy or breastfeeding as it can harm the fetus or infant.
- Liver Impairment: Caution is advised in patients with liver problems, and liver function should be monitored.
Storage:
Store Anaday 1mg Tablet at room temperature (20°C to 25°C), away from moisture and heat.
Conclusion:
Anaday 1mg Tablet (Anastrozole) is an effective treatment for estrogen receptor-positive breast cancer in postmenopausal women. Regular monitoring for bone density and liver function is essential to ensure safe and effective use.
400mg Pazonat Pazopanib Tablet
Minimum Order Quantity: 10 Bottle
Product Brochure
| Dose/Strength | 400 mg |
| Form | Tablet |
| Brand | Natco |
| Pack Type | Box |
| Pack Size | 20 Tablets |
| Shelf Life | 2 Years |
| Usage | Used To Treat Kidney Cancer |
Pazonat 400 mg Tablet (Pazopanib)
Overview:Pazonat 400 mg Tablets contain Pazopanib, a tyrosine kinase inhibitor (TKI) that targets multiple receptors involved in tumor growth and blood vessel formation (angiogenesis). Pazopanib works by inhibiting vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptors, and c-kit, which are crucial for cancer cell proliferation and tumor vascularization. This helps to slow down the progression of various cancers, including renal cell carcinoma (RCC) and soft tissue sarcoma (STS).
Indications:Pazonat 400 mg Tablets are indicated for:
- Renal Cell Carcinoma (RCC): For the treatment of advanced or metastatic RCC in adults, either as a first-line therapy or for patients who have failed previous treatments.
- Soft Tissue Sarcoma (STS): For the treatment of advanced STS in adults after prior chemotherapy, excluding gastrointestinal stromal tumors (GISTs).
- Other Cancers: Pazopanib may also be used off-label for other cancers under the supervision of an oncologist.
Pazopanib works by inhibiting the action of several tyrosine kinases involved in the growth and spread of cancer. By blocking VEGF receptors, it impairs the formation of new blood vessels (angiogenesis) necessary for tumors to grow. Additionally, it targets PDGF receptors and c-kit, preventing cancer cells from dividing and spreading. This combination of effects reduces tumor size and prevents further cancer progression.
Dosage and Administration:- Recommended Dose: The usual dose of Pazonat 400 mg is one tablet daily, taken with or without food.
- Administration: Swallow the tablet whole with water. Do not chew or crush the tablet. It should be taken consistently at the same time each day to ensure effective treatment.
- Common Side Effects: Diarrhea, nausea, vomiting, fatigue, hypertension, liver enzyme elevation, and hair color changes.
- Serious Side Effects: Liver toxicity, heart problems (QT interval prolongation), hemorrhage, and blood clots. Regular monitoring of liver function, blood pressure, and heart rhythm is recommended during treatment.
- Liver Disease: Use with caution in patients with liver impairment, as Pazopanib can cause liver toxicity.
- Heart and Blood Pressure Monitoring: Pazopanib can affect heart function and cause hypertension. Regular monitoring of blood pressure and heart health is necessary.
- Pregnancy and Lactation: Pazopanib is not recommended during pregnancy due to potential harm to the fetus. It is also excreted in breast milk, so breastfeeding should be avoided during treatment.
Store Pazonat 400 mg Tablets at room temperature (15°C to 30°C), away from light, moisture, and out of the reach of children.
Conclusion:Pazonat 400 mg Tablets (Pazopanib) are an effective treatment for advanced renal cell carcinoma and soft tissue sarcoma, as well as other cancers. While it can significantly slow tumor growth and improve survival, it is important to monitor for side effects, including liver toxicity and hypertension. Adherence to dosing schedules and regular medical check-ups are essential for optimal therapy.
Healpecia 1 Finasteride Tablet
Product Brochure
| Strength | 1 mg |
| Usage/Application | Clinical Use |
| Packaging Type | Box |
| Brand | Healing Pharma |
| Shelf Life | 24 Months |
| Product Packaging Size | 30x10 Tablets |
| Medicine brand | Healpecia-1 |
| Medicine form | Tablets |
| Medicine name | Finasteride tablets |
| Medicine strength | 1mg |
| Packaging size | 10 tablets |
| Packaging type | Box |
| Salt composition | Finasteride tablets ip 1mg |
Diane-35 Cyproterone Ethinyl Estradiol Tablet
Product Brochure
| Hormone Strength | 2 mg + 0.035 mg |
| Cycle Pack | 21 tablets |
| Pack Size | 21 Tablets |
| Brand | Bayer |
| Strength | 2 mg / 35 mcg |
| Pack Type | Box |
| Usage/Application | Treatment Of Moderate To Severe Acne |
| Form Of Medicines | Tablet |
| Shelf Life | 5 Years |
150mg Canrib Olaparib Tablet
Product Brochure
| Strength | 150 mg |
| Dose/Strength | 150 mg |
| Brand | Canrib |
| Tablets per Pack | 60 Tablets |
| Usage/Application | Clinical |
| Form | Tablet |
| Packaging Type | Box |
| Packaging Size | 60 tablets |
Canrib Olaparib 150 mg Tablets
Overview:Canrib 150 mg Tablets contain Olaparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of advanced ovarian cancer and other cancers with BRCA1/2 mutations. Olaparib works by blocking the PARP enzyme, which plays a critical role in repairing DNA damage in cells. In cancer cells, particularly those with defective BRCA genes, blocking PARP leads to accumulation of DNA damage, ultimately causing cancer cell death. Olaparib is used to treat patients with cancers that have specific genetic mutations, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.
Indications:Canrib 150 mg Tablets are indicated for:
- Ovarian Cancer: In patients with BRCA-mutated ovarian cancer who have been previously treated with chemotherapy.
- Breast Cancer: For patients with BRCA1/2 mutations and metastatic breast cancer who have been treated with chemotherapy.
- Pancreatic Cancer: For patients with BRCA mutations and metastatic pancreatic cancer after chemotherapy.
- Prostate Cancer: For patients with BRCA mutations and metastatic castration-resistant prostate cancer.
Olaparib is a PARP inhibitor that works by inhibiting the PARP enzyme, which is essential for repairing single-strand DNA breaks. In normal cells, the repair mechanisms work to fix DNA damage, but in cancer cells with BRCA mutations, these repair pathways are already compromised. By inhibiting PARP, Olaparib causes accumulation of DNA damage in cancer cells, leading to cell death, while sparing normal healthy cells.
Dosage and Administration:- Recommended Dose: The typical dose of Canrib 150 mg is one tablet taken twice daily (total dose of 300 mg per day).
- Administration: The tablet should be swallowed whole with a glass of water and can be taken with or without food. It is important to take Canrib consistently at the same time each day to ensure maximum effectiveness.
- Common Side Effects: Nausea, fatigue, anemia, decreased appetite, vomiting, and diarrhea.
- Serious Side Effects: Myelodysplastic syndrome (MDS), acute leukemia, pneumonitis, and bone marrow suppression. Blood counts should be monitored regularly, especially during the initial treatment phase.
- Bone Marrow Suppression: Regular blood tests are required to monitor blood cell counts. Dose adjustments may be necessary if blood counts drop significantly.
- Liver Disease: Caution is advised in patients with liver dysfunction, as Olaparib is metabolized in the liver.
- Pregnancy and Lactation: Olaparib is contraindicated during pregnancy (Category D). Women of childbearing age should use effective contraception during treatment. Avoid breastfeeding during treatment with Canrib.
Store Canrib Olaparib 150 mg Tablets at room temperature (15°C to 30°C), away from light and moisture. Keep out of reach of children.
Conclusion:Canrib Olaparib 150 mg Tablets are an effective treatment for cancers with BRCA mutations, including ovarian, breast, pancreatic, and prostate cancers. By inhibiting PARP, Olaparib helps prevent cancer cells from repairing their DNA, leading to cancer cell death. Regular blood tests and monitoring for side effects such as bone marrow suppression are important for safe use.
100mg Imalek Imatinib Mesylate Tablets
Product Brochure
| Strength | 100 mg |
| Dose/Strength | 100 mg |
| Brand | Imalek |
| Tablets per Pack | 10 Tablets |
| Packaging Size | 10 Tablets |
| Packaging Type | Box |
| Form | Tablet |
| Shelf Life | 2 Yearsd |
| Usage | Cancer Treatment |
| Brand Name | Sun Pharma |
Imalek Imatinib 100mg Tablets
Overview:
Imalek (Imatinib 100mg Tablets) is an oral medication used to treat various cancers, primarily chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), and gastrointestinal stromal tumors (GISTs). Imatinib is a tyrosine kinase inhibitor that works by blocking abnormal proteins responsible for cancer cell growth, which helps prevent the spread of cancer.
Indications:
Imalek 100mg Tablets are indicated for:
- Chronic Myelogenous Leukemia (CML): For newly diagnosed or chronic phase CML.
- Acute Lymphoblastic Leukemia (ALL): Specifically for Philadelphia chromosome-positive (Ph+) ALL.
- Gastrointestinal Stromal Tumors (GISTs): For unresectable or metastatic GISTs expressing the KIT protein.
- Other cancers: Includes hypereosinophilic syndrome and chronic eosinophilic leukemia.
Mechanism of Action:
Imatinib targets and inhibits BCR-ABL tyrosine kinase, an enzyme produced by cancer cells, particularly in CML. This enzyme is crucial for cancer cell growth. By blocking it, Imatinib prevents the signaling pathways that promote cell division, leading to tumor shrinkage and cancer cell death.
Dosage and Administration:
- Recommended Dose: For CML, the usual dose is 400 mg daily, taken with food. For GISTs, doses range from 400 mg to 800 mg based on patient response.
- Administration: Take once daily, with or without food.
- Missed Dose: If missed, take as soon as possible unless it's near the next dose. Do not double the dose.
Side Effects:
Common effects include nausea, vomiting, diarrhea, muscle cramps, and fatigue. Serious effects can include hepatotoxicity, cardiac problems, bone marrow suppression, and allergic reactions.
Precautions:
- Heart conditions: Caution in patients with heart disease.
- Liver function: Monitor liver enzymes.
- Pregnancy: Contraindicated due to potential fetal harm.
Monitoring:
Regular blood tests to monitor for anemia, thrombocytopenia, and liver function.
Storage:
Store at room temperature (20°C to 25°C) in a dry place. Keep out of reach of children.
Conclusion:
Imalek (Imatinib 100mg Tablets) is a highly effective treatment for cancers such as CML, ALL, and GISTs. Monitoring is essential for minimizing side effects.
Lamivudine & Zidovudine Tablets ( Douvir Tablets)
Product Brochure
| Brand | Douvir |
| Pack Size | 60 Tablets in 1 Bottle |
| Brand Name | Douvir |
| Manufacturer By | Cipla Ltd |
| Treatment | Ongoing Hepatitis B Infection (HBV) Contamination |
| Strength | 150mg/300mg |
| Salt Composition | Lamivudine 150mg & Zidovudine 300mg |
Douvir Tablets (Lamivudine & Zidovudine)
Overview: Douvir is a combination antiretroviral medication that contains lamivudine and zidovudine, used in the treatment of HIV-1 infection. This combination helps to suppress viral replication and improve immune function.
Indications:
- HIV Infection: Indicated for the treatment of HIV-1 infection in adults and pediatric patients as part of a comprehensive antiretroviral therapy regimen.
Mechanism of Action:
- Lamivudine: A nucleoside reverse transcriptase inhibitor (NRTI) that inhibits reverse transcriptase, preventing the conversion of viral RNA into DNA.
- Zidovudine: Another NRTI that also inhibits reverse transcriptase and blocks viral replication.
Dosage and Administration:
- Recommended Dose: The typical dosage is usually one tablet taken orally twice daily, but specific recommendations may vary based on individual patient needs.
- Administration: Can be taken with or without food. It’s important to maintain consistency in timing for optimal effectiveness.
Side Effects: Common side effects may include:
- Nausea
- Fatigue
- Headache
- Dizziness
- Anemia (low red blood cell count)
- Neutropenia (low white blood cell count)
Warnings and Precautions:
- Hematologic Toxicity: Monitor blood counts regularly, as both lamivudine and zidovudine can cause bone marrow suppression.
- Liver Function: Regular monitoring of liver function is recommended, particularly in patients with pre-existing liver conditions.
- Hypersensitivity Reactions: Be alert for signs of serious allergic reactions.
Contraindications:
- Hypersensitivity to lamivudine, zidovudine, or any components of the formulation.
- Use with caution in patients with a history of significant bone marrow suppression.
Drug Interactions: Douvir may interact with other medications, particularly those that also affect bone marrow function or are metabolized by the liver. Inform your healthcare provider about all medications being taken.
Storage Instructions: Store at room temperature, away from moisture and light. Keep out of reach of children.
Patient Counseling Information:
- Advise patients to take the medication as prescribed and not to miss doses, as adherence is crucial for viral suppression.
- Discuss the importance of regular follow-up appointments for monitoring blood counts and overall health.
- Instruct patients to report any unusual side effects, particularly signs of anemia or infection.
Douvir Tablets (Lamivudine & Zidovudine) are an important treatment option for managing HIV-1 infection. Proper dosing, monitoring for side effects, and patient education are essential for optimizing treatment outcomes. Always consult a healthcare provider for personalized treatment recommendations.
Selepeg Selexipag 200mcg Tablets
Product Brochure
| Strength | 200 mcg |
| Usage | Pulmonary Arterial Hypertension |
| Brand | Selepag |
| Packaging Size | 1*10 Tablets in 1 Box |
| Composition | Selexipag 200 mcg |
| Manufacturer | MSN Laboratories |
| Treatment | Pulmonary Arterial Hypertension (PAH) |
Selepeg (Selexipag) 200 mcg Tablets
OverviewSelepeg contains selexipag, a medication used primarily for the treatment of pulmonary arterial hypertension (PAH). It functions as a selective agonist of the prostacyclin receptor, helping to dilate blood vessels and reduce blood pressure in the pulmonary arteries.
Indications- Pulmonary Arterial Hypertension (PAH): Indicated for the treatment of adults with PAH to delay disease progression and reduce the risk of hospitalization due to PAH-related complications.
Selexipag mimics the action of prostacyclin, a naturally occurring substance that helps to relax and widen blood vessels. By activating the prostacyclin receptor, selexipag improves blood flow and reduces pulmonary artery pressure.
Dosage and Administration- Typical Dosage: The recommended starting dose is usually 200 mcg taken orally twice daily. The dose may be titrated based on the patient's response and tolerability, with a maximum dose typically not exceeding 1600 mcg per day.
- Administration: Tablets should be taken consistently, either with or without food. Swallow the tablets whole; do not crush or chew.
- Common Side Effects:
- Headache
- Diarrhea
- Nausea
- Jaw pain
- Flushing
- Serious Side Effects:
- Severe hypotension (low blood pressure)
- Increased risk of bleeding (due to effects on platelets)
- Liver enzyme elevation
- Hypersensitivity to selexipag or any component of the formulation.
- Severe hepatic impairment.
- Monitor blood pressure regularly due to the risk of hypotension.
- Liver function tests may be necessary to monitor for hepatic impairment.
- Store at room temperature (20°C to 25°C / 68°F to 77°F) in a dry place, away from light.
- Educate patients about potential side effects, particularly headache and gastrointestinal symptoms, and advise them to report any severe reactions.
- Discuss the importance of adhering to the prescribed dosage and the need for regular follow-up appointments.
Selepeg (selexipag) is an effective treatment option for pulmonary arterial hypertension, helping to improve patient outcomes by enhancing blood flow and reducing pressure in the lungs. Proper administration and monitoring are crucial for maximizing therapeutic benefits. Always consult a healthcare provider for personalized medical advice.
4mg Barijak Baricitinib Tablet
Product Brochure
| Strength | 4 mg |
| Strength / Dose | 4 mg |
| Brand | Barijak |
| Composition | Baricitinib 4 mg |
| Packaging Size | 14 Tablets |
| Usage | For Covid Treatment |
| Form | Tablet |
| Pack Type | Box |
| Brand Name | Natco |
| Shelf Life | 2 Years |
Overview:
4mg Barijak (Baricitinib) Tablet contains Baricitinib, a Janus kinase (JAK) inhibitor used to treat moderate to severe rheumatoid arthritis and other inflammatory conditions. Baricitinib works by selectively inhibiting JAK1 and JAK2 enzymes, which are involved in the signaling pathways of various cytokines and growth factors. This inhibition helps reduce inflammation, pain, and damage in conditions like rheumatoid arthritis.
Indications:
4mg Barijak (Baricitinib) Tablet is indicated for:
- Rheumatoid Arthritis (RA): For adults with moderate to severe RA who have had an inadequate response to or are intolerant of methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
- Atopic Dermatitis: Approved for moderate to severe cases in adults and children 12 years or older (in some regions).
- COVID-19: In some cases, used for severe or critical COVID-19 in patients requiring oxygen support.
Mechanism of Action:
Baricitinib selectively inhibits JAK1 and JAK2 enzymes, which play a crucial role in the signaling of pro-inflammatory cytokines and immune responses. By blocking these enzymes, Baricitinib reduces the activity of immune cells involved in the inflammatory process, thereby controlling symptoms and slowing disease progression.
Dosage and Administration:
- Rheumatoid Arthritis: 4 mg once daily, with or without food. The dose can be reduced to 2 mg daily based on tolerance and the presence of side effects.
- Atopic Dermatitis: 2 mg to 4 mg once daily, depending on the severity of the condition.
- COVID-19: Follow the specific guidelines and dosing recommendations based on clinical status (typically initiated in hospitalized patients).
Side Effects:
Common side effects include:
- Upper respiratory tract infections, headache, and nausea.
- Diarrhea, acne, and high blood pressure.
Serious side effects may include:
- Increased risk of infections (e.g., tuberculosis, bacterial, fungal infections).
- Blood clots, heart problems, and liver enzyme elevations.
- Cancer risk: Possible increased risk of certain cancers with long-term use.
Precautions:
- Infection risk: Screen for tuberculosis and other infections before starting treatment.
- Liver and kidney function: Monitor liver enzymes and renal function during treatment.
- Pregnancy: Baricitinib is contraindicated during pregnancy due to potential harm to the fetus.
Storage:
Store at room temperature (20°C–25°C) in a tightly closed container, away from moisture and light.
Conclusion:
4mg Barijak (Baricitinib) Tablet is an effective treatment for rheumatoid arthritis and certain inflammatory conditions, improving symptoms and slowing disease progression. Regular monitoring for infections, blood counts, and organ function is essential to ensure safe use.
Osimertinib Tablet (Tagrisso 40 mg Tablet)
Product Brochure
| Strength | 40 mg |
| Tablets per Pack | 30 Tablets |
| Packaging Size | 30*1 Tablets |
| Brand | Tagrisso |
| Composition | Osimertinib 40 mg |
| Manufacturer | AstraZeneca |
| Treatment | Non-small Cell Lung Cancer |
| Medicine brand | Tagrisso |
| Medicine form | Tablet |
| Medicine name | Osimertinib tablets |
| Medicine strength | 40mg |
| Packaging size | 10 |
| Packaging type | Box |
Finrest-5 Finasteride Tablet
Product Brochure
| Strength | 5 mg |
| Manufacturer | John Lee |
| Usage/Application | Clinical Use |
| Packaging Size | 10*10 Tablets |
| Form | Tablet |
| Brand | Finrest |
| Packaging Type | Box |
| Shelf Life | 24 Months |
| Medicine form | Tablet |
| Medicine name | Finasteride tablets ip |
| Packaging size | 10 x 10 tablets |
| Packaging type | Box |
200mcg Uptravi Selexipag Tablets
Product Brochure
| Strength | 200 mcg |
| Packaging Size | 140 Tablets |
| Packaging Type | Box |
| Brand | Actelion |
| Shelf life | 24 Months |
| Usage | Used In Treatment Of Pulmonary Arterial Hypertension |
| Form | Tablet |
Uptravi (Selexipag 200mcg Tablets)
Overview:
Uptravi 200mcg Tablet contains Selexipag, a selective prostacyclin IP receptor agonist used primarily in the treatment of pulmonary arterial hypertension (PAH). PAH is a condition characterized by elevated blood pressure in the arteries of the lungs, which can lead to heart failure and reduced exercise capacity. Selexipag works by activating the prostacyclin receptor, resulting in vasodilation of pulmonary arteries, reducing pulmonary vascular resistance, and improving blood flow. This helps alleviate symptoms and improves overall exercise capacity in patients with PAH.
Indications:
Uptravi 200mcg Tablets are indicated for:
- Pulmonary Arterial Hypertension (PAH): To delay disease progression and improve exercise capacity in patients with PAH, either as monotherapy or in combination with other PAH treatments.
Mechanism of Action:
Selexipag is a prostacyclin IP receptor agonist. By binding to the prostacyclin receptor on smooth muscle cells in the pulmonary vasculature, Selexipag mimics the action of natural prostacyclin. This results in vasodilation, reduced pulmonary vascular resistance, and improvement in symptoms of PAH. It also inhibits platelet aggregation and reduces inflammation, contributing to overall cardiovascular health.
Dosage and Administration:
- Pulmonary Arterial Hypertension (PAH):
The starting dose is 200mcg twice daily.
The dose may be gradually increased by 200mcg every week as tolerated, up to a maximum of 1,600mcg twice daily. - Administration: Take tablets with or without food. Swallow the tablets whole with a glass of water. Do not chew or crush the tablets.
Side Effects:
Common side effects include:
- Headache, nausea, diarrhea, and jaw pain.
- Flushing, muscle pain, and fatigue. Serious side effects may include:
- Liver toxicity: Liver function tests should be monitored regularly.
- Hypotension and arrhythmias: Particularly when starting or increasing the dose.
- Bleeding risk: Selexipag may increase the risk of bleeding, especially in patients with a history of bleeding disorders.
Precautions:
- Liver Function: Monitor liver enzymes regularly due to the risk of hepatotoxicity.
- Renal Impairment: Use with caution in patients with moderate renal impairment.
- Bleeding Risks: Selexipag should be used with caution in patients at risk for bleeding.
- Pregnancy and Breastfeeding: Selexipag is contraindicated during pregnancy and breastfeeding due to potential risks to the fetus and infant.
- Dose Titration: Selexipag should be titrated carefully to minimize side effects during the initiation and dose escalation phases.
Storage:
Store Uptravi 200mcg Tablets at room temperature (20°C to 25°C), away from moisture and light. Keep out of reach of children.
Conclusion:
Uptravi (Selexipag 200mcg Tablets) is a valuable treatment for pulmonary arterial hypertension (PAH). It works by activating the prostacyclin receptor to reduce pulmonary vascular resistance and improve exercise capacity. Regular monitoring for liver function, bleeding risks, and proper dose titration are crucial for safe and effective treatment.
View More